OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Results of Operations and Financial ConditionItem 2.02 — Results of Operations and Financial Condition.
On May 8, 2018, OpGen, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2018. The full text of such press release is furnished as Exhibit 99.1 to this report.
The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 — Financial Statements and Exhibits.
| 99.1 |
Press Release, dated May 8, 2018 issued by OpGen, Inc.
|
OPGEN INC ExhibitEX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1 OPGEN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Revenue increases 10% to $0.8 million,…To view the full exhibit click here
About OpGen, Inc. (NASDAQ:OPGN)
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.
